132 related articles for article (PubMed ID: 19239230)
1. Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.
Lund BW; Knapp AE; Piu F; Gauthier NK; Begtrup M; Hacksell U; Olsson R
J Med Chem; 2009 Mar; 52(6):1540-5. PubMed ID: 19239230
[TBL] [Abstract][Full Text] [Related]
2. Retinoic acid receptor beta,gamma-selective ligands: synthesis and biological activity of 6-substituted 2-naphthoic acid retinoids.
Yu KL; Spinazze P; Ostrowski J; Currier SJ; Pack EJ; Hammer L; Roalsvig T; Honeyman JA; Tortolani DR; Reczek PR; Mansuri MM; Starrett JE
J Med Chem; 1996 Jun; 39(12):2411-21. PubMed ID: 8691435
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist.
Lund BW; Piu F; Gauthier NK; Eeg A; Currier E; Sherbukhin V; Brann MR; Hacksell U; Olsson R
J Med Chem; 2005 Dec; 48(24):7517-9. PubMed ID: 16302793
[TBL] [Abstract][Full Text] [Related]
4. Structure, function and modulation of retinoic acid receptor beta, a tumor suppressor.
Alvarez S; Germain P; Alvarez R; Rodríguez-Barrios F; Gronemeyer H; de Lera AR
Int J Biochem Cell Biol; 2007; 39(7-8):1406-15. PubMed ID: 17433757
[TBL] [Abstract][Full Text] [Related]
5. Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility.
Chen J; Ding K; Levant B; Wang S
Bioorg Med Chem Lett; 2006 Jan; 16(2):443-6. PubMed ID: 16290142
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and structure-activity relationship of novel RXR-selective modulators.
Michellys PY; D'Arrigo J; Grese TA; Karanewsky DS; Leibowitz MD; Mais DA; Mapes CM; Reifel-Miller A; Rungta D; Boehm MF
Bioorg Med Chem Lett; 2004 Mar; 14(6):1593-8. PubMed ID: 15006411
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and evaluation of hexahydrobenz[f]isoquinolines as a novel class of dopamine 3 receptor ligands.
Wu X; Chen J; Ji M; Varady J; Levant B; Wang S
Bioorg Med Chem Lett; 2004 Dec; 14(23):5813-6. PubMed ID: 15501046
[TBL] [Abstract][Full Text] [Related]
8. Design of selective nuclear receptor modulators: RAR and RXR as a case study.
de Lera AR; Bourguet W; Altucci L; Gronemeyer H
Nat Rev Drug Discov; 2007 Oct; 6(10):811-20. PubMed ID: 17906643
[TBL] [Abstract][Full Text] [Related]
9. Pyrazine arotinoids with inverse agonist activities on the retinoid and rexinoid receptors.
García J; Khanwalkar H; Pereira R; Erb C; Voegel JJ; Collette P; Mauvais P; Bourguet W; Gronemeyer H; de Lera AR
Chembiochem; 2009 May; 10(7):1252-9. PubMed ID: 19343742
[TBL] [Abstract][Full Text] [Related]
10. An RPE cell line as a useful in vitro model for studying retinoic acid receptor beta: expression and affinity.
Pavan B; Dalpiaz A; Biondi C; Nieddu M; De Luca A; Prasad PD; Paganetto G; Favaloro B
Biosci Rep; 2008 Dec; 28(6):327-34. PubMed ID: 18673301
[TBL] [Abstract][Full Text] [Related]
11. Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta.
Hangeland JJ; Doweyko AM; Dejneka T; Friends TJ; Devasthale P; Mellström K; Sandberg J; Grynfarb M; Sack JS; Einspahr H; Färnegårdh M; Husman B; Ljunggren J; Koehler K; Sheppard C; Malm J; Ryono DE
Bioorg Med Chem Lett; 2004 Jul; 14(13):3549-53. PubMed ID: 15177471
[TBL] [Abstract][Full Text] [Related]
12. 7-Substituted 2-phenyl-benzofurans as ER beta selective ligands.
Collini MD; Kaufman DH; Manas ES; Harris HA; Henderson RA; Xu ZB; Unwalla RJ; Miller CP
Bioorg Med Chem Lett; 2004 Oct; 14(19):4925-9. PubMed ID: 15341953
[TBL] [Abstract][Full Text] [Related]
13. Selective retinoic acid receptor ligands for rheumatoid arthritis.
Beehler BC; Brinckerhoff CE; Ostrowski J
Curr Opin Investig Drugs; 2004 Nov; 5(11):1153-7. PubMed ID: 15573865
[TBL] [Abstract][Full Text] [Related]
14. RAR and RXR modulation in cancer and metabolic disease.
Altucci L; Leibowitz MD; Ogilvie KM; de Lera AR; Gronemeyer H
Nat Rev Drug Discov; 2007 Oct; 6(10):793-810. PubMed ID: 17906642
[TBL] [Abstract][Full Text] [Related]
15. Rational design of highly active and selective ligands for the alpha5beta1 integrin receptor.
Heckmann D; Meyer A; Laufer B; Zahn G; Stragies R; Kessler H
Chembiochem; 2008 Jun; 9(9):1397-407. PubMed ID: 18481343
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of novel 3-hydroxy-cyclobut-3-ene-1,2-dione derivatives as thyroid hormone receptor beta (TR-beta) selective ligands.
Raval S; Raval P; Bandyopadhyay D; Soni K; Yevale D; Jogiya D; Modi H; Joharapurkar A; Gandhi N; Jain MR; Patel PR
Bioorg Med Chem Lett; 2008 Jul; 18(14):3919-24. PubMed ID: 18585912
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel subtype selective RAR agonists.
Piu F; Gauthier NK; Olsson R; Currier EA; Lund BW; Croston GE; Hacksell U; Brann MR
Biochem Pharmacol; 2005 Dec; 71(1-2):156-62. PubMed ID: 16303118
[TBL] [Abstract][Full Text] [Related]
18. Identification of a series of benzoxazoles as potent 5-HT6 ligands.
Liu KG; Lo JR; Comery TA; Zhang GM; Zhang JY; Kowal DM; Smith DL; Di L; Kerns EH; Schechter LE; Robichaud AJ
Bioorg Med Chem Lett; 2009 Feb; 19(4):1115-7. PubMed ID: 19152787
[TBL] [Abstract][Full Text] [Related]
19. Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors.
Pinard E; Alberati D; Borroni E; Fischer H; Hainzl D; Jolidon S; Moreau JL; Narquizian R; Nettekoven M; Norcross RD; Stalder H; Thomas AW
Bioorg Med Chem Lett; 2008 Sep; 18(18):5134-9. PubMed ID: 18752953
[TBL] [Abstract][Full Text] [Related]
20. Refinement of histamine H3 ligands pharmacophore model leads to a new class of potent and selective naphthalene inverse agonists.
Roche O; Nettekoven M; Vifian W; Sarmiento RM
Bioorg Med Chem Lett; 2008 Aug; 18(15):4377-9. PubMed ID: 18606542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
